Covalon Technologies Ltd. (COV) - Total Assets
Based on the latest financial reports, Covalon Technologies Ltd. (COV) holds total assets worth CA$32.80 Million CAD (≈ $23.73 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Covalon Technologies Ltd. - Total Assets Trend (2005–2025)
This chart illustrates how Covalon Technologies Ltd.'s total assets have evolved over time, based on quarterly financial data. Also see market value of Covalon Technologies Ltd. for the company's overall valuation and market capitalisation.
Covalon Technologies Ltd. - Asset Composition Analysis
Current Asset Composition (September 2025)
Covalon Technologies Ltd.'s total assets of CA$32.80 Million consist of 87.3% current assets and 12.7% non-current assets. Review debt load of Covalon Technologies Ltd. to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 48.1% |
| Accounts Receivable | CA$5.84 Million | 16.2% |
| Inventory | CA$7.40 Million | 20.5% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$1.35 Million | 3.7% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Covalon Technologies Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Covalon Technologies Ltd. stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Covalon Technologies Ltd.'s current assets represent 87.3% of total assets in 2025, an increase from 26.0% in 2005.
- Cash Position: Cash and equivalents constituted 48.1% of total assets in 2025, up from 14.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 20.5% of total assets.
Covalon Technologies Ltd. Competitors by Total Assets
Key competitors of Covalon Technologies Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.68 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥1.17 Billion |
|
Embecta Corp
NASDAQ:EMBC
|
USA | $1.27 Billion |
Covalon Technologies Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.69 | 8.12 | 0.67 |
| Quick Ratio | 4.29 | 5.94 | 0.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$22.87 Million | CA$28.10 Million | CA$-7.43 Million |
Covalon Technologies Ltd. - Advanced Valuation Insights
This section examines the relationship between Covalon Technologies Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.04 |
| Latest Market Cap to Assets Ratio | 1.49 |
| Asset Growth Rate (YoY) | 13.6% |
| Total Assets | CA$36.12 Million |
| Market Capitalization | $53.86 Million USD |
Valuation Analysis
Above Book Valuation: The market values Covalon Technologies Ltd.'s assets above their book value (1.49x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Covalon Technologies Ltd.'s assets grew by 13.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Covalon Technologies Ltd. (2005–2025)
The table below shows the annual total assets of Covalon Technologies Ltd. from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | CA$36.12 Million ≈ $26.13 Million |
+13.57% |
| 2024-09-30 | CA$31.81 Million ≈ $23.01 Million |
+27.73% |
| 2023-09-30 | CA$24.90 Million ≈ $18.01 Million |
-18.03% |
| 2022-09-30 | CA$30.38 Million ≈ $21.98 Million |
-25.14% |
| 2021-09-30 | CA$40.58 Million ≈ $29.36 Million |
+16.96% |
| 2020-09-30 | CA$34.70 Million ≈ $25.10 Million |
-12.40% |
| 2019-09-30 | CA$39.61 Million ≈ $28.65 Million |
+100.97% |
| 2018-09-30 | CA$19.71 Million ≈ $14.26 Million |
+64.68% |
| 2017-09-30 | CA$11.97 Million ≈ $8.66 Million |
+84.43% |
| 2016-09-30 | CA$6.49 Million ≈ $4.69 Million |
-14.96% |
| 2015-09-30 | CA$7.63 Million ≈ $5.52 Million |
-4.15% |
| 2014-09-30 | CA$7.96 Million ≈ $5.76 Million |
+40.41% |
| 2013-09-30 | CA$5.67 Million ≈ $4.10 Million |
-4.92% |
| 2012-09-30 | CA$5.96 Million ≈ $4.31 Million |
-36.03% |
| 2011-09-30 | CA$9.32 Million ≈ $6.74 Million |
-9.67% |
| 2010-09-30 | CA$10.32 Million ≈ $7.47 Million |
-19.80% |
| 2009-09-30 | CA$12.87 Million ≈ $9.31 Million |
-25.59% |
| 2008-09-30 | CA$17.29 Million ≈ $12.51 Million |
-14.58% |
| 2007-09-30 | CA$20.24 Million ≈ $14.64 Million |
+130.22% |
| 2006-09-30 | CA$8.79 Million ≈ $6.36 Million |
+95.39% |
| 2005-09-30 | CA$4.50 Million ≈ $3.26 Million |
-- |
About Covalon Technologies Ltd.
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company's platform technologies comprises collagen matrix platform that is used to manufacture a family of products to… Read more